Don't forget, we don't know how long the "due diligence" period has been going on.
Anytime in Nov, Dec, Jan or early Feb.
They are not obligated to tell shareholders that a "due diligence phase" with one/more companies is being done.
Lets hope everything is in order and it gets completed soon.
With the current AMPA research discussed and the possibilities. If a company gives a small upfront and not much of a back-end loaded deal for RD but the upfront is enough to finish SA with good results, it would allow Cortex to shop around to their content for SA. It would not be in any companies interest to low ball Cortex in a RD deal where if good SA results come out, Cortex could take a different company up on an offer.
If the upfront is small enough to finish SA but the deal is loaded at the back, the share price will adjust accordingly and financing if needed will be done at better prices.
A big worry is, we haven't been privileged to see what the FDA letter in response to CX717 was and we haven't been privileged to read the toxicology tests done on the compounds. So we only know what we've been told and there can be a lot that we don't know.
From what has been released, I am extremely optimistic and things have been discussed repeated and rationally here many times but there is a little grey spot where we may not know things as clearly as we think we might.
As far as the OT topics regarding the economy, I am happy that there are so many good posters here and enjoy reading most, but I'd rather not read about the economy when looking to read about Cortex news. Today I think Bernanke stated he feels the markets and the recession may turn around before the end of this year.
When oil was 130, there was no end of people saying it will go to 150 and 200. There are people who say gold will go to 1500 and 2000. When the dow was rising, people were saying DOW 20K here we come, now people are saying DOW 5k. There is a guy on TV hocking natural cures for diabetes, arthritis and other diseases. All of these people are either fantastic orators or great at assimilating data to support their idea. Unless they are talking about biotech financing or Cortex or are trying to relate one to Cortex, I'd rather read about it on businessweek or watch it on TV.
